|
N-Nitrosamine Formation in Pharmaceutical Drug Products: Development and Validation of a Biased, Conservative, Predictive Model-Pub
|
|
2
|
93
|
November 20, 2025
|
|
Hunt for NDSRIs: Unveiling Hidden Threats with the Novel 15N-Enriched NAP Test-Pub
|
|
1
|
153
|
November 20, 2025
|
|
In Vitro Metabolism Study of NDSRIs
|
|
3
|
125
|
November 20, 2025
|
|
Studies addressing potential bioactivation and genotoxicity liabilities of the N-nitroso derivative of the antidepressant paroxetine-Pub
|
|
0
|
45
|
November 18, 2025
|
|
N-nitrosamides, N-nitrosoureas, Nnitrosoguanidines
|
|
6
|
307
|
November 11, 2025
|
|
WHO Updates on Nitrosamine Impurities
|
|
0
|
332
|
October 30, 2025
|
|
N-Nitroso Sertraline
|
|
9
|
808
|
October 23, 2025
|
|
Analytical challenge for determination of instable standard of other N-nitroso structure
|
|
10
|
647
|
September 22, 2025
|
|
Modeling the Impact of Excipients Selection on Nitrosamine Formation towards Risk Mitigation
|
|
18
|
4903
|
September 20, 2025
|
|
Nitrosamines risk in cleaning validation approach
|
|
11
|
323
|
September 4, 2025
|
|
Ask for help with limit for Nitroso-olaparib
|
|
2
|
183
|
September 4, 2025
|
|
👨💻 Quantitative Analysis of NDMA, N-Nitroso-l-ephedrine and N-Nitroso-pseudoephedrine in Pseudoephedrine Hydrochloride by HPLC-Tandem MS
|
|
2
|
411
|
August 28, 2025
|
|
Three-Pronged Approach (Active Pharmaceutical Ingredients, Excipients, and NOx-Free Air) Successfully Suppressed the Formation of Nitroso-atomoxetine to 0.097 ppm
|
|
0
|
418
|
August 24, 2025
|
|
N-nitroso-Duloxetine recall back in the news!
|
|
20
|
4207
|
August 18, 2025
|
|
Testing of N-nitroso-cinacalcet
|
|
6
|
822
|
May 25, 2025
|
|
Primary amines in formation of nitrosamine
|
|
6
|
771
|
August 13, 2025
|
|
Nitrosamine Risk Mitigation Calculator (by DFE Pharma)
|
|
1
|
942
|
August 11, 2025
|
|
🇺🇸 FDA - Fiscal Year 2024 Generic Drug Science and Research Initatives Public Workshop
|
|
21
|
2090
|
August 7, 2025
|
|
Highlights from the 13th meeting of the Nitrosamine Implementation Oversight Group (NIOG)
|
|
7
|
488
|
July 22, 2025
|
|
Genotoxicity evaluation of ten nitrosamine drug substance-related impurities using 2D and 3D HepaRG cells -Pub
|
|
0
|
254
|
July 12, 2025
|
|
CMO Nitrosamine Risk Assessment
|
|
7
|
438
|
June 27, 2025
|
|
Analytical Method Development Strategy for Controlling Two New Nitrosamine Drug Substance Related Impurities (NDSRIs) in a Pharmaceutical Drug Product for Treatment of a Rare Disease -Pub
|
|
0
|
95
|
June 25, 2025
|
|
Optimizing Pharmaceutical Formulations: Strategies for Improving Stability and Minimizing Nitrosamine Impurities-Webinar
|
|
1
|
306
|
June 20, 2025
|
|
Using N-Nitrosodiethanolamine (NDELA) and N-Nitrosopiperidine (NPIP) Transgenic Rodent Gene Mutation Data and Quantum Mechanical Modeling to Derive Potency-Based Acceptable Intakes for NDSRIs Lacking Robust Carcinogenicity Data-Pub
|
|
0
|
215
|
June 6, 2025
|
|
N-Nitroso Abemaciclib
|
|
8
|
347
|
June 4, 2025
|
|
¹⁵N-Enriched NAP Test
|
|
0
|
219
|
May 31, 2025
|
|
N-nitroso Torasemide Impurity formation and control
|
|
33
|
2397
|
May 27, 2025
|
|
Optimizing the detection of N-nitrosamine mutagenicity in the Ames test -Pub
|
|
17
|
740
|
May 23, 2025
|
|
N-Nitroso Spinosad Impurity-A and Impurity-D
|
|
2
|
209
|
May 21, 2025
|
|
🇲🇽 Free Lhasa México Symposia: Shaping the Future of Pharma & Regulation 🇲🇽
|
|
0
|
118
|
May 13, 2025
|